After the business changed the trial’s eligibility requirements, Celyad Oncology (NASDAQ:CYAD) reported that the FDA had released a clinical hold on a phase 1b trial of its CAR T cell treatment CYAD-101.
Following the news, the premarket price of Celyad Oncology stock increased by 35.06 percent to $2.35 on August 1.
The Market Seems Thrilled by the Trial News
The FDA put a clinical hold on the CYAD-101-002, also known as (KEYNOTE-B79), colorectal cancer research in March to look into reports of two fatalities in the trial. The study was conducted in conjunction with Merck (NYSE:MRK).
Celyad had claimed in February that the trial was voluntarily suspended while an investigation into the two fatalities was conducted.
In patients with refractory metastatic colorectal cancer and microsatellite stable/mismatch-repair proficient illness, the combination of CYAD-101 with Keytruda (pembrolizumab) will be assessed.
Charles Morris, chief medical officer at Celyad, stated that the business is still optimistic about the future growth of both the candidate and the ongoing development of our unique TIM technology. Officials from the firm intends to continue showcasing their proficiency with non-gene edited technologies and investigate further potential to use NKG2D in allogeneic CAR T since CYAD-101 is presently the only clinical candidate co-expressing NKG2D and TIM.
Featured Image: Megapixl @Anyaberkut